Walleye Capital LLC Aerie Pharmaceuticals Inc Transaction History

Walleye Capital LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$6.37 - $15.23 $3.59 Million - $8.59 Million	-564,180 Reduced 89.34%	67,310 $1.02 Million
Q2 2022 Aug 08, 2022	BUY	$4.95 - $9.16 $1.79 Million - $3.32 Million	362,380 Added 134.66%	631,490 $4.74 Million
Q1 2022 May 16, 2022	SELL	$5.64 - $9.8 $604,681 - $1.05 Million	-107,213 Reduced 28.49%	269,110 $2.45 Million
Q4 2021 Mar 03, 2022	BUY	$7.02 - $13.33 $724,878 - $1.38 Million	103,259 Added 37.81%	376,323 $2.64 Million
Q3 2021 Nov 15, 2021	BUY	$11.32 - $16.63 $3.09 Million - $4.54 Million	273,064 New	273,064 $3.11 Million
Q1 2021 May 17, 2021	SELL	$13.12 - $20.9 $1.02 Million - $1.63 Million	-77,800 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$9.12 - $14.49 $618,308 - $982,378	67,797 Added 677.77%	77,800 $1.05 Million
Q2 2019 Aug 14, 2019	BUY	$28.97 - $48.21 $289,786 - $482,244	10,003 New	10,003 $296,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.